ARTICLE | Clinical News
Venclexta venetoclax: Phase Ib data
May 23, 2016 7:00 AM UTC
Data from 34 evaluable treatment-naive AML patients ages >65 in an open-label, dose-escalation, international Phase Ib trial showed that once-daily oral Venclexta plus decitabine or azacitidine led to...